Linus Pauling, a two-time Nobel laureate, was both celebrated and criticized for his late-career advocacy of high-dose vitamin C as a cancer treatment in the 1970s. While initial skepticism—fueled by failed Mayo Clinic trials in the late 1970s and early 1980s—relegated his ideas to the fringes of alternative medicine, recent research suggests Pauling may have been onto something, albeit with critical nuances overlooked in his time. This article delves into the science, context, and broader implications of vitamin C in oncology, uncovering connections to affordable therapies and systemic challenges in conventional cancer care.

Pauling’s collaboration with Scottish physician Ewan Cameron involved administering high-dose vitamin C intravenously (IV) to terminal cancer patients, reporting extended survival and improved quality of life. However, the Mayo Clinic’s randomized controlled trials (RCTs), which tested oral vitamin C, found no benefit, seemingly discrediting Pauling’s claims. What was missed—and what the original coverage often fails to highlight—is the critical difference in delivery method. IV administration achieves blood concentrations up to 100 times higher than oral intake, as the gut limits absorption. At these levels, vitamin C shifts from an antioxidant to a pro-oxidant, generating hydrogen peroxide that selectively damages cancer cells under oxidative stress, a mechanism supported by lab studies (Riordan et al., 1995).

Recent clinical research offers mixed but intriguing results. A 2014 Phase I trial (Ma et al., published in Science Translational Medicine) with 27 ovarian cancer patients showed that IV vitamin C, combined with chemotherapy, reduced toxicity and suggested improved survival, though the sample size limits generalizability. Another 2017 study (Monti et al., in Frontiers in Oncology) on pancreatic cancer patients (n=14) found similar tolerability and potential synergy with standard treatments, but again, small cohorts and lack of large-scale RCTs temper conclusions. Study quality remains a concern—most are early-phase or observational, lacking the rigor of large RCTs, and funding often comes from institutions with no clear conflicts of interest, though alternative therapy advocacy groups occasionally play a role.

What’s missing from mainstream discourse is the systemic context. Pauling’s push for vitamin C wasn’t just a scientific hypothesis; it was a challenge to an oncology establishment often resistant to low-cost, non-patentable interventions. This echoes broader patterns in alternative therapies—think of the slow acceptance of aspirin for cardiovascular health or dietary interventions for chronic disease—where profit-driven pharmaceutical models can delay exploration of accessible solutions. Vitamin C, costing pennies per gram compared to chemotherapies priced at thousands per dose, raises questions about research priorities. Why have large-scale IV vitamin C trials lagged despite decades of interest? The answer likely lies in funding structures and the lack of financial incentive for industry stakeholders.

Moreover, Pauling’s story reflects a cultural tension between genius and overreach. His ‘halo effect’ criticism—expertise in chemistry not translating to medicine—ignores how interdisciplinary thinking often drives innovation. Modern oncology increasingly embraces metabolic and oxidative stress targets (e.g., ketogenic diets in glioblastoma research), paralleling Pauling’s focus on biochemical vulnerabilities in cancer cells. His error was in overpromising without robust data, not in the core idea of exploiting cancer’s unique weaknesses.

The evidence today suggests IV vitamin C isn’t a cure but could be a low-risk, low-cost adjunct for specific cancers, particularly in resource-limited settings. Yet, without large-scale RCTs (ideally n>500) to confirm efficacy and safety—especially regarding risks like kidney strain in vulnerable patients—it remains experimental. The oncology community must balance skepticism with curiosity, ensuring affordable options aren’t dismissed due to systemic bias rather than scientific merit.